Last reviewed · How we verify
NCT06149988
Comparative PK Study Of THC/CBD Formulations
Phase 1 trial testing THC/CBD S.E powder in Cannabis in 14 participants. Status unknown.
1 February 2024
Quick facts
| Lead sponsor | CapSoil |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 27 August 2023 |
| Primary completion | 1 February 2024 |
| Estimated completion | 1 February 2024 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- THC/CBD S.E powder — full drug profile →
- THC/CBD oil — full drug profile →
Conditions studied
- Cannabis — all drugs for Cannabis →
Sponsor
CapSoil — full company profile →
Who can join
Adults 21 to 65, any sex, with Cannabis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A phase I, single center crossover study. The goal of this clinical trial is to learn about self-emulsified THC/CBD powder compared with equivalent dose of THC/CBD oil, orally administerd in healthy volunteers. The main question it aims to answer is: •If the pharmacokinetics profile of one dose of THC/CBD Self emulsified (S.E powder) compares to THC/CBD oil (equivalent dose). The secondary is: •If the use of THC/CBD S.E powder is tolerable and safe at least as THC/CBD oil. Participants will receive a single dose of THC/CBD S.E powder followed by a 30-day washout period and then a single dose of THC/CBD oil.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Enhancing cannabinoid bioavailability: a crossover study comparing a novel self-nanoemulsifying drug delivery system and a commercial oil-based formulation.
Hermush V, Mizrahi N, Brodezky T, Ezra R. · · 2025 · cited 5× · PMID 40514741 · DOI 10.1186/s42238-025-00294-8
Verify or expand the search:
- PubMed search for NCT06149988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cannabis
Currently open trials in the same condition.
- NCT05999383 — Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration · Phase 2 · recruiting
- NCT07417059 — Sex Hormones Impact on Cannabis Response · NA · recruiting
- NCT07194018 — Use of Cannabis Oil in Fibromyalgia · active not recruiting
- NCT06099379 — Modulation of THC Effects by CBD: a Dose-ranging Study · Phase 1, PHASE2 · recruiting
- NCT05742724 — The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06149988 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CapSoil
- Last refreshed: 29 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06149988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing